Though still over a month away I am gearing up for BI0 2008 and yes blogging is part of the plan however, I will be posting ‘tweets’ via Twitter documenting my live experiences throughout the entire conference, as opposed to regular blog posts that I will get to at the end of the days. Twitter [...]

• 390http://clsdf.com/2008/05/bio2008-twitter-follow-me-arubenstein/BIO2008+%2B+Twitter+%3D+Follow+Me+%40arubenstein2008-05-08+01%3A50%3A00admin

With over $116M in cash on the books as-of 31 March that did not keep management at Array BioPharma (NASDAQ: ARRY) from securing an additional $80M debt facility from Deerfield Management. Deerfield currently holds in excess of 4.7M shares of Array or nearly 10% of the company. This new debt round will be drawn down [...]

• 389http://clsdf.com/2008/05/array-biopharma-secures-80m-debt-facility/Array+BioPharma%3A+Secures+%2480M+Debt+Facility2008-05-06+14%3A31%3A00admin

You may (or may not) know that the May edition of BioBeers will be held in Boulder. At the moment BioBeers, Inc. is in the process of securing BioBus transportation from Denver to Boulder and back. Please take a few minutes to indicate on the side-bar survey (left column on BioBeers.com if you are reading [...]

• 388http://clsdf.com/2008/05/attention-thirsty-denver-biobeers-attendees/Attention+Thirsty+Denver+BioBeers+Attendees%212008-05-05+21%3A06%3A00admin

The pre-event planning material for the BIO 2008 conference is pouring in fast and furious. (Do you plan to attend? Would you like to meet? Please contact me to arrange arubenstein@rnaventures.com). So whilst perusing the Product Focus Zone publication I was incredibly excited to see BaroFold (Boulder) highlighted in the Protein Therapeutics chapter. Jeff Cleland, [...]

• 387http://clsdf.com/2008/05/it%e2%80%99s-starting-to-look-a-lot-like-bio%e2%80%a6/It%E2%80%99s+Starting+to+Look+a+lot+Like+BIO%E2%80%A62008-05-05+14%3A29%3A00admin

Among the core assets that Gilead (Nasdaq: GILD) acquired from Myogen in 2006 for $2.5B was Letairis® (ambrisentan), for the treatment of pulmonary arterial hypertension (PAH), which was then approved by the FDA in mid 2007. After about a quarter in the market Gilead has initiated a Phase IV, randomized, double-blind, placebo-controlled study evaluating Letairis® [...]

• 386http://clsdf.com/2008/05/off-to-phase-iv-for-letairis%c2%ae-and-the-market-for-volibris%c2%ae/Off+to+Phase+IV+for+Letairis%C2%AE+and+the+Market+for+Volibris%C2%AE2008-05-02+15%3A01%3A00admin

It is one week to go till BioBootCamp 2008 begins…are you ready to get your life-science start-up or start-up ideas in shape? Have you applied to attend? BioBootCamp is more than a 2-day business seminar, it is designed to help you jump start your new life science idea or company, this experience will provide you [...]

• 385http://clsdf.com/2008/05/biobootcamp-2008-drop-and-give-me-50/BioBootCamp+2008%3A+Drop+and+Give+Me+50%212008-05-01+14%3A21%3A00admin